RBC Capital analyst Conor McNamara initiated coverage of Thermo Fisher with an Outperform rating and $661 price target. He sees the company becoming "a one-stop-shop for future biopharma research and drug development" by combining their historical assets in life science research with recent acquisitions in the CDMO, CRO, and diagnostics spaces, McNamara tells investors. Thermo being able to offer customers solutions for every step of the drug approval process "puts the company in an advantageous position," the analyst added.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TMO:
- Thermo Fisher price target lowered to $570 from $575 at Barclays
- Follow the Hedge Fund: Top Manager Ray Dalio Placed Big Bucks on These 5 Stocks
- Lone Pine adds Autodesk stake, reduces Meta Platforms, Microsoft stakes
- Society for Immunotherapy of Cancer to hold a meeting
- Thermo Fisher authorizes $4B in share repurchases
